Amylyx Pharmaceuticals reported positive results from its latest clinical trial on Tuesday. The study evaluated the effectiveness of an experimental drug named avexitide for patients suffering from post-bariatric hypoglycemia, a condition characterized by dangerous, sudden drops in blood sugar levels.
Data from the Phase 3 trial show that participants receiving avexitide experienced a 55% reduction in serious low blood sugar events compared to those in the placebo group. The trial was originally powered to demonstrate a 35% improvement, meaning the actual clinical results exceeded expectations.
For patients with this condition, these events are medical emergencies. Serious episodes can lead to loss of consciousness or seizures. Amylyx co-CEO Justin Klee stated that any reduction in these events is significant for both patients and their families. He described the magnitude of the effect observed in the study as highly encouraging.
This outcome clears a path for potential regulatory approval. If approved, avexitide would become the first available treatment specifically indicated for post-bariatric hypoglycemia. The success of this trial represents a move forward for patients who currently lack standard medical options for managing these glucose fluctuations after bariatric procedures.